

CLAIMS

1. A composition for parenteral administration comprising a mammalian plasma and hyaluronic acid or a salt or ester thereof, characterized in that said plasma comprises lipids and/or phospholipids.
- 5 2. The composition according to claim 1, characterized in that said lipids and/or phospholipids are present in the plasma at a total concentration of between 0.2 and 7 mg/ml.
3. The composition according to claim 1 or 2, characterized in that said plasma comprises minor plasma lipids, preferably at a total concentration of between 5 and 50 nmol/l.
- 10 4. The composition according to any one of the preceding claims 1-3, characterized in that said minor plasma lipids are chosen from the group of palmitoyl ethanolamide (PEA), stearoyl ethanolamide (SEA), arachidonoyl ethanolamide (AEA).
- 15 5. The composition according to any one of the preceding claims 1-4, characterized in that said plasma has an anti-hemophilic factor (factor VIII) activity higher than 75 %
6. The composition according to any one of the preceding claims 1-5, characterized in that said plasma has a fibrinogen concentration ranging between 0.25 and 3 g/l.
- 20 7. The composition according to any one of the preceding claims 1-6, characterized in that said plasma has an activated partial thromboplastin time (aPTT) activity ranging between 12 and 65 sec and/or a partial thromboplastin time (PTT) activity ranging between 5 and 17 sec.
- 25 8. The composition according to any one of the preceding claims 1-7, characterized in that said plasma is mammalian derived, more preferably derived from equine, bovine, porcine, ovine, canine, or feline blood.
9. The composition according to any one of the preceding claims 1-8, characterized in that said composition further comprises one or more pharmaceutical compounds, wherein said compounds are selected from the group consisting of an active pharmaceutical ingredient, an antibiotic agent, a cell composition, a small organic molecule, a protein, and a peptide.
- 30 10. The composition according to any one of the preceding claims 1-9, characterized in that said pharmaceutical active compound is an alpha-2 adrenergic receptor agonist, preferably clonidine or a derivative thereof, preferably clonidine.
- 35

11. The composition according to any one of the preceding claims 1-10, characterized in that said composition further comprises a calcium source, preferably calcium chloride.
12. The composition according to any one of the preceding claims 1-11,
5 characterized in that said cell composition is chosen from mesenchymal stem cells, osteoprogenitor cells, osteoblasts, osteocytes, chondroblasts and/or chondrocytes.
13. The composition according to any one of the preceding claims 1-12,
10 characterized in that said small organic molecule is a scaffold or matrix component with osteoconductive properties, preferably tricalcium phosphate particles (TCP).
14. A kit comprising one or more aliquots of a composition, said composition comprising a mammalian plasma comprising lipids and/or phospholipids, and hyaluronic acid or a salt or ester thereof and optionally one or more
15 pharmaceutical active ingredients, selected from the group consisting of a pharmaceutical active compound, a cell composition, or a small organic molecule, and wherein said composition is in a powder form, and wherein said kit further comprises one or more aliquots of a calcium source, preferably a calcium chloride solution.
- 20 15. The kit according to claim 14, characterized in that said plasma comprises minor plasma lipids, wherein said minor plasma lipids are chosen from the group of palmitoyl ethanolamide (PEA), stearyl ethanolamide (SEA), arachidonoyl ethanolamide (AEA).
- 25 16. The composition according to any one of the preceding claims 1 to 13 or the kit according to claims 14 to 15 for use in the treatment of a musculoskeletal disease, preferably a bone disease or a joint disease.
17. The composition or the kit according to claim 16 for use in the treatment of osteoarthritis.
- 30 18. The composition or the kit according to claim 16 for use in the treatment or prevention of cranial cruciate ligament rupture.
19. The composition or the kit according to claim 16 for use in the treatment of tendinopathies.
- 35 20. The composition or kit for use according to claim 16-19, wherein a sufficient amount of the composition is dissolved in a sufficient amount of a calcium source, thereby obtaining a solution, said solution is administered to a subject, said administration is preferably parenteral.